Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Alexion Pharma

Biotech companies Amgen and Alexion Pharmaceuticals reportedly reached an agreement in a patent battle over blockbuster rare-disease drug Soliris. ALXN stock popped Thursday.

Alexion Jumps After Reportedly Settling Amgen Patent Battle

Gilead Sciences

Moderna

GlaxoSmithKline

Many biotech companies are coming up with impressive reports on their development of drugs, vaccines and therapies for COVID-19.

Coronavirus Vaccine Development Gathers Steam: 4 Winners

As biotechnology stocks surge, traders advice investors to be selective.

Tread carefully if you're buying biotech stocks, traders say as group nears all-time highs

THOUSAND OAKS, Calif., May 20, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced voting results from the Company's Annual Meeting of Stockholders on May 20, 2020, held virtually this year due to the COVID-19 pandemic. More than 88 percent of outstanding shares were represented at...

Amgen Announces Voting Results Of Annual Meeting Of Stockholders

Adaptive Biotechnologies

CytoDyn Inc.

Regeneron Pharmaceuticals

Drugmakers and biotech companies are initiating development of drugs, vaccines and therapies for COVID-19 and substantial progress has been made over the past month.

5 Biotech Stocks in Focus as Race for Coronavirus Vaccine Heats Up

Bristol-Myers

Novartis

Roche Holding AG

Our Chief Picks In Pharma

Amgen (AMGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Amgen (AMGN) Upgraded to Buy: What Does It Mean for the Stock?

Allogene Therapeutics Inc

Arvinas Inc

CytomX Therapeutics

MacroGenics

The American Society of Clinical Oncology annual conference brings together oncology professionals, patient advocates, industry representatives, and major media outlets from across the globe.

5 ASCO Abstracts Moving Biopharma Stocks

The biotech giant is back on track after a strong first quarter.

Is Now Still a Good Time To Buy Amgen?

Amgen stock is forming a cup base as it takes a two-pronged approach to coronavirus treatment, partnering with Adaptive Biotechnologies and testing Otezla in Covid-19. Is Amgen stock a buy?

Biotech Amgen Is Tackling Coronavirus From Two Sides — But Is It A Buy?

AbbVie

Biotech stocks are often high-risk, high-reward investments that have binary outcomes based on one or a handful of drug or device candidates in development.

Biotech Stock Rally Is Crushing Short Sellers

Amgen's stock ripped higher in April. Here's why.

Why Amgen Soared in April

BioMarin Pharmaceutical

Eli Lilly

Vertex Pharmaceuticals

Biopharma shares have outperformed the broader market year-to-date, giving rise to apprehension over whether a pullback is in the offing.

5 Biopharmas Where BofA Would Put Its Money To Work

Amgen (AMGN) beats estimates for both earnings and sales. It maintains its previously-issued financial guidance for 2020.

Amgen (AMGN) Q1 Earnings Top, to Study Otezla for Coronavirus

Amgen Inc. (NASDAQ: AMGN) reported stronger than expected financial results on Thursday that initially pushed share prices up roughly 2% in after-hours trading but the stock settled around 0.5% lower than the price at which it closed the regular session. Amgen also announced on Thursday that it plans on testing Otezla (psoriasis drug) as a potential treatment for the novel respiratory disease that Coronavirus causes.

Amgen says it will test Otezla for COVID-19 as it posts an upbeat Q1 earnings report

Amgen reported better-than-expected first-quarter results and said it plans to study psoriasis drug Otezla as a potential treatment for Covid-19, the respiratory disease caused by the new coronavirus.

Amgen is studying Otezla for coronavirus; its first-quarter results beat Street estimates

Amgen Inc. (AMGN) CEO Bob Bradway on Q1 2020 Results - Earnings Call Transcript

Amgen Inc  on Thursday reported better-than-expected first-quarter results and said it plans to study psoriasis drug Otezla as a potential treatment for COVID-19, the respiratory disease caused by the new coronavirus.

Amgen studying Otezla for coronavirus, looking into other treatments

Amgen (AMGN) delivered earnings and revenue surprises of 12.70% and 2.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Amgen (AMGN) Q1 Earnings and Revenues Surpass Estimates

Amgen Inc. AMGN, +1.37% shares advanced in the extended session Thursday after the biotech drug maker topped Wall Street estimates for the quarter.

Amgen stock ticks higher after earnings beat

Amgen stock rose late Thursday after the biotech reported adjusted income of $4.17 per share on $6.16 billion in first-quarter sales.
The post Amgen Pops As Biotech Behemoth Tops Earnings Views And Keeps Outlook appeared first on Investor's Business Daily.

Amgen Pops As Biotech Behemoth Tops Earnings Views And Keeps Outlook

Amgen Inc  on Thursday reported better-than-expected first-quarter results on Thursday and said it plans to study psoriasis drug Otezla as a potential treatment for COVID-19, the respiratory disease caused by the new coronavirus.

Amgen studying Otezla for coronavirus, first-quarter results beat Street estimates

Boston Scientific

Quest Diagnostics

Owens & Minor

Stryker

In spite of Covid-19 and global recession concerns, we have a positive outlook on the biotechnology sub-industry; we expect to see a ramp-up in new drug sales; the continued development of many new, innovative therapies; and a decline in the prevalence of patent expirations in 2020 and 2021.

News for Amgen Stock (AMGN)